These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29653813)

  • 41. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
    Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
    Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
    Powles T; Motzer RJ; Escudier B; Pal S; Kollmannsberger C; Pikiel J; Gurney H; Rha SY; Park SH; Geertsen PF; Gross-Goupil M; Grande E; Suarez C; Markby DW; Arroyo A; Dean M; Choueiri TK; George D
    Br J Cancer; 2018 Sep; 119(6):663-669. PubMed ID: 30197417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
    Sternberg CN; Motzer RJ; Hutson TE; Choueiri TK; Kollmannsberger C; Bjarnason GA; Paul Nathan ; Porta C; Grünwald V; Dezzani L; Han J; Tannir NM
    Clin Genitourin Cancer; 2019 Dec; 17(6):425-435.e4. PubMed ID: 31601514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
    Verbiest A; Couchy G; Job S; Zucman-Rossi J; Caruana L; Lerut E; Oyen R; de Reyniès A; Laguerre B; Rioux-Leclercq N; Wozniak A; Joniau S; Van Poppel H; Van Den Eynde K; Beuselinck B
    Clin Genitourin Cancer; 2018 Jun; 16(3):e605-e612. PubMed ID: 29239846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
    Racsa PN; Whisman TR; Worley K
    Curr Med Res Opin; 2015; 31(10):1933-40. PubMed ID: 26368665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
    Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
    Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
    Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
    J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
    Cao X; Tang D; Ratto B; Poole A; Ravichandran S; Jin L; Gao W; Swallow E; Vogelzang NJ
    Clin Genitourin Cancer; 2020 Feb; 18(1):e37-e45. PubMed ID: 31727510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience.
    Ekenel M; Karabulut S; Cil I; Zırtıloglu A; Aydın E; Tural D
    Actas Urol Esp (Engl Ed); 2020; 44(1):27-33. PubMed ID: 31744648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
    Buti S; Bersanelli M; Maines F; Facchini G; Gelsomino F; Zustovich F; Santoni M; Verri E; De Giorgi U; Masini C; Morelli F; Vitale MG; Sava T; Prati G; Librici C; Fraccon AP; Fornarini G; Maruzzo M; Leonardi F; Caffo O
    Clin Genitourin Cancer; 2017 Aug; 15(4):e609-e614. PubMed ID: 28108284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
    Powles T; Sarwar N; Stockdale A; Sarker SJ; Boleti E; Protheroe A; Jones R; Chowdhury S; Peters J; Oades G; O'Brien T; Sullivan M; Aitchison M; Beltran L; Worth D; Smith K; Michel C; Trevisan G; Harvey-Jones E; Wimalasingham A; Sahdev A; Ackerman C; Crabb S
    JAMA Oncol; 2016 Oct; 2(10):1303-1309. PubMed ID: 27254750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
    Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
    Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
    Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
    Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
    Frampton JE
    Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.